Primaquine Shortage: What Providers and Prescribers Need to Know in 2026

Primaquine remains the cornerstone of anti-relapse therapy for Plasmodium vivax and Plasmodium ovale malaria, yet many patients struggle to fill their prescriptions at standard retail pharmacies. For prescribers in infectious disease, travel medicine, and primary care, understanding the current primaquine supply landscape is essential for effective patient counseling and care planning in 2026.

Current Availability Status: What the Data Shows

As of 2026, primaquine phosphate 26.3 mg tablets are not listed as an active shortage on either the FDA Drug Shortage Database or the ASHP Drug Shortage Bulletin. Multiple generic manufacturers supply the US market. The commercial supply chain is currently intact.

That said, your patients will frequently report that their local retail pharmacy does not carry the drug. This is not a shortage — it is a structural stocking problem driven by primaquine's niche therapeutic footprint in the US market, where malaria is not endemic. Providers should proactively set patient expectations and have a pharmacy referral strategy ready at the time of prescribing.

Why Primaquine Remains Structurally Difficult to Access

Several compounding factors explain primaquine's persistent pharmacy availability problem:

Concentrated prescribing population. Primaquine prescriptions are concentrated among infectious disease specialists, travel medicine clinics, and tropical medicine programs — a small patient volume relative to the broader pharmacy network. Most retail pharmacies adjacent to these practices see insufficient demand to justify routine stocking.

G6PD screening prerequisite. The mandatory G6PD testing requirement before dispensing adds a clinical and operational step that further limits the pharmacies willing and equipped to handle primaquine prescriptions routinely. Hemolytic anemia in G6PD-deficient patients is a serious and potentially life-threatening risk.

Limited manufacturer base with concentrated API sourcing. Like many mature generic drugs, primaquine's active pharmaceutical ingredient (API) comes from a concentrated set of overseas suppliers, primarily in Asia. Any GMP compliance issue, geopolitical disruption, or manufacturing delay at these facilities can create supply vulnerability that rapidly propagates to the US market.

CDC distribution discontinuation. The historical role of the CDC Drug Service in distributing primaquine during supply stress has been discontinued, leaving the commercial market as the sole pathway for US patients.

Therapeutic Alternatives: When Primaquine Cannot Be Obtained

For radical cure of P. vivax and P. ovale, the therapeutic options are limited. Providers should be familiar with the following:

Tafenoquine (Krintafel): FDA-approved (2018) for radical cure of P. vivax in patients ≥16 years with G6PD activity confirmed by quantitative testing. Single 300 mg dose offers significant adherence advantage over primaquine's 14-day regimen. Requires quantitative G6PD testing (point-of-care qualitative tests are insufficient for tafenoquine dosing decisions). Substantially higher cost than generic primaquine.

Weekly primaquine (mild-moderate G6PD deficiency): Per CDC guidance, patients with mild-to-moderate G6PD deficiency who require anti-relapse therapy may receive primaquine 45 mg weekly for 8 weeks with close hematological monitoring. This requires baseline CBC and monitoring at days 3 and 8.

Chloroquine suppressive therapy: For patients with G6PD deficiency who cannot receive either primaquine or tafenoquine, the CDC recommends chloroquine 300 mg base weekly for 1 year as a suppressive strategy. This does not achieve radical cure but prevents relapse clinically by suppressing parasitemia.

Key Prescribing Considerations and Safety Reminders

Mandatory G6PD testing: G6PD testing must be performed before initiating primaquine in every patient. For primaquine, qualitative testing (screen) is minimally acceptable; quantitative testing is preferred and required before tafenoquine. Document testing results in the patient record.

Baseline and monitoring labs: Obtain baseline hemoglobin/hematocrit before initiating therapy. For patients with mild-moderate G6PD deficiency on the weekly regimen, CBC monitoring at day 3 and day 8 is required.

Pregnancy and breastfeeding: Primaquine is contraindicated in pregnancy (fetal G6PD status unknown). For breastfeeding patients, it is contraindicated if the infant is G6PD-deficient or G6PD status is unknown.

Drug interactions: Quinacrine is absolutely contraindicated with primaquine. QTc-prolonging agents, CYP3A4 inhibitors (clarithromycin, idelalisib), and strong CYP3A4 inducers (apalutamide, carbamazepine) warrant clinical consideration.

A Strategy for Proactive Patient Support

Given primaquine's stocking challenges, we recommend a proactive pharmacy referral approach at the time of prescribing. Consider directing patients to hospital outpatient pharmacies, travel medicine clinic pharmacies, or specialty pharmacies in your network. medfinder for providers can also help your patients locate nearby pharmacies with primaquine in stock, reducing the number of patients who return to your office or call your line frustrated about prescription access.

For a detailed walkthrough of strategies to help your patients access primaquine, see our provider's guide to helping patients find primaquine in stock.